Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs RD06 05 (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Churg-Strauss syndrome; Dermatomyositis; Diffuse scleroderma; Granulomatosis with polyangiitis; Immune-mediated necrotising myopathy; Microscopic polyangiitis; Multiple sclerosis; Myasthenia gravis; Myositis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
- Focus Adverse reactions
- Sponsors Nanjing Bioheng Biotech
- 21 Jan 2025 New trial record